AARP Illinois

Chicago, IL. – With Americans losing tens of billions of dollars annually to investment fraud schemes, what mindsets and behaviors are common among those who fall victim? A new survey by the AARP Fraud Watch Network finds that the most susceptible typically exhibit an unusually high degree of confidence in unregulated investments and tend to trade more actively than the general investor population. More of the investment scam victims also reported that they value wealth accumulation as a significant measure of success in life and acknowledged being open to unsolicited telephone and email sales pitches.

Illinois State Director Bob Gallo spoke with Illinois News Network providing insight into the proposed new tax on retirement income.

AARP Illinois State Director, Bob Gallo, was a guest on Illinois News Connection speaking about the concerns that AARP has around ideas like Medicare vouchers.

In our quest to understand and improve brain health, the old adage remains true: What’s good for the heart is good for the brain.

Honor the Deal

CHICAGO — AARP today launched a comprehensive campaign to protect Medicare in the face of proposals by some in Congress that would hurt hardworking Illinoisans who have paid into the program their entire working lives.

CHICAGO– Beginning today through April 18, AARP Foundation is providing free tax assistance and preparation through its Tax-Aide program. AARP Foundation Tax-Aide, in its 49th year, is the nation’s largest free tax assistance and preparation service, offering free tax preparation help to anyone, especially those who are 50 and older, who cannot afford a tax preparation service.

For too long Illinois has been without a comprehensive, balanced budget that helps make life better for residents of all ages.

When you’ve done all you can to protect your joints but the pain continues to interfere with every day activities, it may be time to consider joint replacement surgery.

You may have heard in the news that yet another Alzheimer’s drug has failed to show efficacy in a large clinical trial. Pharmaceutical company Eli Lilly announced last month that their drug Solanezumab had failed its second trial.